

Company registration number 03888024 (England and Wales)

**CAMBRIDGE RESEARCH BIOCHEMICALS LIMITED**  
**UNAUDITED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 JANUARY 2023**  
**PAGES FOR FILING WITH REGISTRAR**

# **CAMBRIDGE RESEARCH BIOCHEMICALS LIMITED**

## **CONTENTS**

---

	<b>Page</b>
Balance sheet	1 - 2
Statement of changes in equity	3
Notes to the financial statements	4 - 11

---

# CAMBRIDGE RESEARCH BIOCHEMICALS LIMITED

## BALANCE SHEET

AS AT 31 JANUARY 2023

	Notes	2023 £	£	2022 £	£
<b>Fixed assets</b>					
Tangible assets	5		925,962		965,877
<b>Current assets</b>					
Stocks		189,153		135,373	
Debtors	6	325,273		369,428	
Investments	7	185,483		195,418	
Cash at bank and in hand		599,735		484,550	
		1,299,644		1,184,769	
<b>Creditors: amounts falling due within one year</b>	8	(331,186)		(294,561)	
<b>Net current assets</b>			968,458		890,208
<b>Total assets less current liabilities</b>			1,894,420		1,856,085
<b>Creditors: amounts falling due after more than one year</b>	9		(515,497)		(637,324)
<b>Provisions for liabilities</b>			(53,891)		(55,690)
<b>Net assets</b>			1,325,032		1,163,071
<b>Capital and reserves</b>					
Called up share capital			747		747
Revaluation reserve			98,242		98,242
Capital redemption reserve			666		666
Profit and loss reserves			1,225,377		1,063,416
<b>Total equity</b>			1,325,032		1,163,071

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.

For the financial year ended 31 January 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

# **CAMBRIDGE RESEARCH BIOCHEMICALS LIMITED**

## **BALANCE SHEET (CONTINUED)**

**AS AT 31 JANUARY 2023**

---

The financial statements were approved and signed by the director and authorised for issue on 6 April 2023

Mrs E J Humphrys  
**Director**

**Company Registration No. 03888024**

# CAMBRIDGE RESEARCH BIOCHEMICALS LIMITED

## STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 JANUARY 2023

	Share capital	Revaluation reserve	Capital redemption reserve	Profit and loss reserves	Total
Notes	£	£	£	£	£
<b>Balance at 1 February 2021</b>	747	98,242	666	883,554	983,209
<b>Year ended 31 January 2022:</b>					
Profit and total comprehensive income for the year	-	-	-	345,932	345,932
Dividends	-	-	-	(166,070)	(166,070)
<b>Balance at 31 January 2022</b>	747	98,242	666	1,063,416	1,163,071
<b>Year ended 31 January 2023:</b>					
Profit and total comprehensive income for the year	-	-	-	321,363	321,363
Dividends	-	-	-	(159,402)	(159,402)
<b>Balance at 31 January 2023</b>	747	98,242	666	1,225,377	1,325,032

# CAMBRIDGE RESEARCH BIOCHEMICALS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS

**FOR THE YEAR ENDED 31 JANUARY 2023**

---

### **1 Accounting policies**

#### **Company information**

Cambridge Research Biochemicals Limited is a private company limited by shares incorporated in England and Wales, company number 03888024. The registered office is 17-19 Belasis Court, Belasis Hall Technology Park, Billingham, United Kingdom, TS23 4AZ.

#### **1.1 Accounting convention**

These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

#### **1.2 Turnover**

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

# CAMBRIDGE RESEARCH BIOCHEMICALS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 JANUARY 2023

### 1 Accounting policies

(Continued)

#### 1.3 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Land and buildings freehold	50 years
Plant and machinery	10% - 33.33% straight line and 15% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

#### 1.4 Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

#### 1.5 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

#### 1.6 Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

#### 1.7 Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

# CAMBRIDGE RESEARCH BIOCHEMICALS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 JANUARY 2023

### 1 Accounting policies

(Continued)

#### **Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

#### **Classification of financial liabilities**

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

#### **Basic financial liabilities**

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

### 1.8 Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

### 1.9 Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

#### **Current tax**

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.



# CAMBRIDGE RESEARCH BIOCHEMICALS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 JANUARY 2023

### 1 Accounting policies

(Continued)

#### **Deferred tax**

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

#### **1.10 Employee benefits**

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

#### **1.11 Retirement benefits**

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

#### **1.12 Leases**

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

#### **1.13 Government grants**

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

#### **1.14 Foreign exchange**

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

# CAMBRIDGE RESEARCH BIOCHEMICALS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 JANUARY 2023

### 2 Judgements and key sources of estimation uncertainty

In the application of the company's accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

### 3 Employees

The average monthly number of persons (including directors) employed by the company during the year was:

	2023 Number	2022 Number
Total	15	13

### 4 Intangible fixed assets

	Goodwill £	Other £	Total £
<b>Cost</b>			
At 1 February 2022 and 31 January 2023	2	3,969	3,971
<b>Amortisation and impairment</b>			
At 1 February 2022 and 31 January 2023	2	3,969	3,971
<b>Carrying amount</b>			
At 31 January 2023	-	-	-
At 31 January 2022	-	-	-

# CAMBRIDGE RESEARCH BIOCHEMICALS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 JANUARY 2023

### 5 Tangible fixed assets

	Land and buildings	Plant and machinery etc	Total
	£	£	£
<b>Cost</b>			
At 1 February 2022	678,000	597,977	1,275,977
Additions	-	47,858	47,858
Disposals	-	(47,407)	(47,407)
At 31 January 2023	678,000	598,428	1,276,428
<b>Depreciation and impairment</b>			
At 1 February 2022	65,560	244,540	310,100
Depreciation charged in the year	9,558	78,215	87,773
Eliminated in respect of disposals	-	(47,407)	(47,407)
At 31 January 2023	75,118	275,348	350,466
<b>Carrying amount</b>			
At 31 January 2023	602,882	323,080	925,962
At 31 January 2022	612,440	353,437	965,877

### 6 Debtors

	2023	2022
	£	£
<b>Amounts falling due within one year:</b>		
Trade debtors	182,307	201,333
Corporation tax recoverable	104,766	91,829
Other debtors	38,200	76,266
	325,273	369,428

### 7 Current asset investments

	2023	2022
	£	£
Other investments	185,483	195,418

# CAMBRIDGE RESEARCH BIOCHEMICALS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 JANUARY 2023

### 8 Creditors: amounts falling due within one year

	2023 £	2022 £
Bank loans	56,505	61,932
Trade creditors	94,046	87,911
Taxation and social security	25,930	18,367
Other creditors	154,705	126,351
	<u>331,186</u>	<u>294,561</u>

### 9 Creditors: amounts falling due after more than one year

	2023 £	2022 £
Bank loans and overdrafts	416,096	499,273
Other creditors	99,401	138,051
	<u>515,497</u>	<u>637,324</u>

Bank loans are secured by way of fixed and floating charges over the assets of the company.

Creditors which fall due after five years are as follows:

	2023 £	2022 £
Payable by instalments	<u>270,360</u>	<u>270,585</u>

### 10 Finance lease obligations

	2023 £	2022 £
Future minimum lease payments due under finance leases:		
Within one year	59,676	47,490
In two to five years	38,276	66,542
	<u>97,952</u>	<u>114,032</u>

# CAMBRIDGE RESEARCH BIOCHEMICALS LIMITED

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 JANUARY 2023

### 11 Government grants

Deferred income is included in the financial statements as follows:

	2023 £	2022 £
Arising from government grants	71,509	81,913
	<u>71,509</u>	<u>81,913</u>
	<u><u>71,509</u></u>	<u><u>81,913</u></u>
	2023 £	2022 £
Current liabilities	10,384	10,404
Non-current liabilities	61,125	71,509
	<u>71,509</u>	<u>81,913</u>
	<u><u>71,509</u></u>	<u><u>81,913</u></u>

### 12 Directors' transactions

Dividends totalling £137,402 (2022 - £140,070) were paid in the year in respect of shares held by the company's directors.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.